Dr Reddys Laboratories Ltd

Overview

• Target: Dr. Reddy's Laboratories Ltd; Acquirer: ICICI Prudential Mutual Fund; PAC: none; Promoter group: No.

Pre-acquisition holding

• Before: 4,13,32,755 shares; 4.952% voting; 4.923% diluted.

Acquisition details

• Acquired: 7,12,884 shares; 0.085% of total shares.

Post-acquisition holding

• After: 4,20,45,639 shares; 5.037% voting; 5.008% diluted.

Market data

• Mode: Open Market; Date: August 12, 2026.

Capital & listing

• Listed on BSE and NSE.
• Equity capital before: 83,46,65,000; after: same.
• Total diluted after: 83,95,32,173.

Resignation: CEO, API and Services

• Change type: Resignation of Deepak Sapra from CEO, API and Services.
• Effective date: close of business hours on November 12, 2026.
• Reason: to pursue opportunities outside the Company.
• Designation held: CEO, API and Services and Senior Management Personnel.
• Relationships with other directors: Not applicable.

Regulatory inspection update

• US FDA completed PAI and GMP inspection at FTO-SEZ Process Unit-02, Srikakulam.
• Inspection conducted between July 20 and July 29, 2026.
• Form 483 issued with three observations; addressed within the stipulated timeline.

Meeting Details

• Date: July 22, 2026; Time: not disclosed.
• Type: group earnings call; Mode: virtual (Zoom).
• Event/organiser: Dr. Reddy’s Laboratories Limited Q1 FY27 Earnings Call.

Participants

• Key participants: CEO; CFO; Head – Investor Relations.

Purpose

• Purpose: discuss Q1 FY27 earnings results for quarter ended June 30, 2026; Q&A with management.

Additional Notes

• Recording and transcript will be available on the company website.
• Session conducted with listen-only mode during opening remarks.

Earnings call recording

• Audio recordings of June 30, 2026 earnings call were released; the call was conducted on July 22, 2026.

Semaglutide impurity update

• Impurity detected in scale-up API for semaglutide; investigation to identify root cause and process tweaks.
• Validation required before resuming commercial supplies; no regulatory filing changes or patient safety impact.
• Timeline: three validation batches and testing; September completion; scale-up may start October; supply by November.
• Expected coverage: 6-7 million pens from Nov–Mar under long-term OneSource arrangement.
• Supply halt through September; no market shipments; no recall; prior shipments remain safe.
• Canadian shipments unaffected to date; future supply constrained due to validation delays.
• OneSource inventory is company-owned; not commercially sold; potential write-down may be required.
• Alternative supplier being qualified; timelines about a year away; not an immediate fix.
• EBITDA guidance unchanged; 20%+ target remains, but period miss reduces near-term sales.

Event details

• Q1 FY27 results for quarter ended June 30, 2026 to be released July 22, 2026 after board meeting.
• Earnings call July 22, 2026 at 19:30 IST; audio and transcript on website.
• Press meet presentation to be available on the company's website.
• Pre-register for earnings call at https://drreddys.zoom.us/webinar/register/WN_xVkKzh0MSyaxs-eKX8_0wg

Meeting Details

• Meeting date: 9 July 2026; time not specified.
• Type and mode: group virtual investor meet.
• Event name: Analyst / Investor Meet.
• Company participants: not disclosed in filing.
• Recording: audio recording available.